Innovative Diagnostic For Babies Wins NICE Early Value Assessment Pilot Backing
An innovative genetic test that can detect which babies are likely to develop deafness if treated with a common antibiotic is set to receive conditional funding in the UK under NICE’s rapid evaluation pilot scheme.
You may also be interested in...
Genomic Tests Eliminate ‘Diagnostic Odysseys’ ̶ Why Are They Underutilized In The UK?
Genomic diagnostics provide significant value to the health system, but England’s unclear funding pathways and commissioning processes are preventing these tests from reaching patients, a report by trade body BIVDA reveals.
How Innovative UTI Diagnostics Can Help Combat Antibiotic Resistance
UTIs are one of the most common reasons for antibiotics to be prescribed, but accurate and timely diagnostic tools are lacking. England’s NICE has identified four innovative IVDs that could be rolled out for NHS patients, but said more research is needed on these products first.
UK’s Early Value Assessment Pilot Is ‘Catalyst’ For Wider Change - NICE
NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.